Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Moodys
McKesson
Baxter
McKinsey
Dow
Medtronic

Last Updated: January 27, 2023

CLINICAL TRIALS PROFILE FOR SACUBITRIL; VALSARTAN


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


All Clinical Trials for Sacubitril; Valsartan

Trial ID Title Status Sponsor Phase Start Date Summary
NCT01920711 ↗ Efficacy and Safety of LCZ696 Compared to Valsartan, on Morbidity and Mortality in Heart Failure Patients With Preserved Ejection Fraction Completed Novartis Pharmaceuticals Phase 3 2014-07-18 The purpose of this study was to evaluate the effect of LCZ696 compared to valsartan in the reduction of cardiovascular death and heart failure(HF) hospitalizations in patients with HF with preserved ejection fraction.
NCT02554890 ↗ Comparison of Sacubitril/Valsartan Versus Enalapril on Effect on NT-proBNP in Patients Stabilized From an Acute Heart Failure Episode. Completed Novartis Pharmaceuticals Phase 4 2016-04-29 The purpose of this study was to assess the effect of in-hospital initiation of sacubitril/valsartan (LCZ696) vs. enalapril on time averaged proportional change in NT-proBNP in patients who have been stabilized following hospitalization for acute decompensated heart failure (ADHF) and reduced ejection fraction (left ventricular ejection fraction (LVEF) ≤ 40%).
NCT02636283 ↗ Use of Entresto Sacubitril/Valsartan for the Treatment of Peripheral Arterial Disease Terminated American Heart Association Phase 2 2017-12-31 This study proposes the use of Entresto (sacubitril/valsartan) to test the effects on pain free walking duration on patients with peripheral arterial disease, a condition caused by decreased blood flow to the muscles in the legs.
NCT02636283 ↗ Use of Entresto Sacubitril/Valsartan for the Treatment of Peripheral Arterial Disease Terminated University of Minnesota Phase 2 2017-12-31 This study proposes the use of Entresto (sacubitril/valsartan) to test the effects on pain free walking duration on patients with peripheral arterial disease, a condition caused by decreased blood flow to the muscles in the legs.
NCT02636283 ↗ Use of Entresto Sacubitril/Valsartan for the Treatment of Peripheral Arterial Disease Terminated University of Minnesota - Clinical and Translational Science Institute Phase 2 2017-12-31 This study proposes the use of Entresto (sacubitril/valsartan) to test the effects on pain free walking duration on patients with peripheral arterial disease, a condition caused by decreased blood flow to the muscles in the legs.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Sacubitril; Valsartan

Condition Name

Condition Name for Sacubitril; Valsartan
Intervention Trials
Heart Failure 28
Hypertension 8
Heart Failure With Preserved Ejection Fraction 7
Heart Failure, Systolic 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Sacubitril; Valsartan
Intervention Trials
Heart Failure 56
Hypertension 7
Myocardial Infarction 6
Infarction 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Sacubitril; Valsartan

Trials by Country

Trials by Country for Sacubitril; Valsartan
Location Trials
United States 249
Spain 45
Italy 42
Japan 36
United Kingdom 35
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Sacubitril; Valsartan
Location Trials
California 10
Massachusetts 10
Tennessee 9
Pennsylvania 9
Virginia 9
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Sacubitril; Valsartan

Clinical Trial Phase

Clinical Trial Phase for Sacubitril; Valsartan
Clinical Trial Phase Trials
Phase 4 37
Phase 3 15
Phase 2/Phase 3 2
[disabled in preview] 18
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Sacubitril; Valsartan
Clinical Trial Phase Trials
Recruiting 33
Completed 21
Not yet recruiting 17
[disabled in preview] 9
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Sacubitril; Valsartan

Sponsor Name

Sponsor Name for Sacubitril; Valsartan
Sponsor Trials
Novartis Pharmaceuticals 20
Brigham and Women's Hospital 4
The Heartbeat Trust 3
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Sacubitril; Valsartan
Sponsor Trials
Other 112
Industry 26
NIH 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter
Dow
Harvard Business School
McKesson
Express Scripts
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.